Screener
Immunome IMNM Total Operating Expenses
Total Operating Expenses at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Immunome’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219425
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | 46,381 | 36,872 |
| General and administrative | 12,950 | 10,690 |
| Total operating expenses | 59,331 | 47,562 |
| Loss from operations | (59,331) | (44,636) |
| Interest income | 5,492 | 2,996 |
| Net loss | $(53,839) | $(41,640) |
| Net loss per share, basic and diluted | $(0.48) | $(0.52) |
Item 1. Financial Statements.
FAQ
- What is Immunome's total operating expenses?
- Immunome (IMNM) reported total operating expenses of $59.33M in Q1 2026.
- How has Immunome's total operating expenses changed year-over-year?
- Immunome's total operating expenses increased by 24.7% year-over-year, from $47.56M to $59.33M.
- What is the long-term trend for Immunome's total operating expenses?
- Over 4 years (2021 to 2025), Immunome's total operating expenses has grown at a 74.0% compound annual growth rate (CAGR), from $25.2M to $231.05M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about Immunome's total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude